Analysts Set Alphatec Holdings, Inc. (NASDAQ:ATEC) PT at $17.00

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been given a consensus rating of “Moderate Buy” by the nine research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $17.00.

Several equities research analysts have issued reports on ATEC shares. Lake Street Capital decreased their price target on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. Morgan Stanley cut shares of Alphatec from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $13.00 price target on shares of Alphatec in a research note on Thursday, October 31st. Piper Sandler decreased their price target on shares of Alphatec from $17.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Thursday, October 31st.

Alphatec Stock Performance

NASDAQ:ATEC opened at $9.13 on Friday. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a 50-day moving average price of $6.22 and a two-hundred day moving average price of $8.42. Alphatec has a twelve month low of $4.88 and a twelve month high of $17.34. The company has a market capitalization of $1.29 billion, a P/E ratio of -7.13 and a beta of 1.31.

Insider Buying and Selling

In related news, Director David M. Demski bought 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The shares were acquired at an average cost of $5.67 per share, with a total value of $283,500.00. Following the completion of the transaction, the director now owns 288,441 shares of the company’s stock, valued at approximately $1,635,460.47. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Comerica Bank lifted its position in Alphatec by 64.8% during the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock valued at $89,000 after buying an additional 2,534 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Alphatec during the first quarter valued at approximately $141,000. Van ECK Associates Corp lifted its position in Alphatec by 11.8% during the second quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock valued at $128,000 after buying an additional 1,300 shares in the last quarter. Cetera Advisors LLC lifted its position in Alphatec by 15.6% during the first quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock valued at $175,000 after buying an additional 1,720 shares in the last quarter. Finally, Net Worth Advisory Group acquired a new position in Alphatec during the third quarter valued at approximately $76,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.